



## Proteomics International

LABORATORIES LTD

ASX/Media Release

16 April 2018

ASX code: PIQ

### Proteomics completes Exercise of Options raising \$3.4 million

- Proteomics International has raised the maximum available amount of \$3.4 million through the exercise of its listed options
- Existing option holders exercised 90% of their entitlements
- Directors exercised more than \$1.0m of their options
- Alto Capital have completed the underwriting for the shortfall of \$341,808 or 10% of the options outstanding

Medical technology company Proteomics International Laboratories Ltd (Proteomics International, ASX: PIQ) announces that it has received \$341,808 from the underwriting of the remaining shortfall from the PIQO options (PIQO). This completes the conversion of all PIQ options raising a total of \$3.4 million before costs.

As announced on 6 April existing Proteomics International option holders took up 90% of available options, leaving 1,709,041 PIQO options that were not exercised by the expiry date of 31 March 2018 (Unexercised PIQO Options).

Managing Director, Dr Richard Lipscombe, said "The Directors wish to express their gratitude to the underwriters and all option holders who supported the Company in this highly successful campaign. These extra funds will help drive the on-going commercialisation of PromarkerD, and accelerate the growth of our business."

Pursuant to the underwriting agreement announced to the ASX on 14 March 2018, the underwriter, Alto Capital has applied for all of the Unexercised PIQO Options, at \$0.20 per option. In accordance with the terms of the agreement, the options were allocated to the underwriter and Proteomics International has issued the shares in accordance with ASX Listing Rule 7.2 (exception 12). Alto Capital had underwritten \$2 million of PIQ options, but the overwhelming support of option holders meant the shortfall was low.

ENDS

#### For further information please contact:

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Paul Hart [Investor Relations]  
Director  
Canary Capital  
T: +61 421 051 474  
E: [phart@canarycapital.com.au](mailto:phart@canarycapital.com.au)

Susan Fitzpatrick-Napier [Media Contact]  
Digital Mantra Group  
T: +61 2 8218 2144  
E: [team@dmgpr.com](mailto:team@dmgpr.com)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

**About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

PILL (ASX: PIQ) is a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company’s business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.